<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35264561</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>09</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Sirtuin-1 sensitive lysine-136 acetylation drives phase separation and pathological aggregation of TDP-43.</ArticleTitle><Pagination><StartPage>1223</StartPage><MedlinePgn>1223</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1223</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-022-28822-7</ELocationID><Abstract><AbstractText>Trans-activation response DNA-binding protein of 43&#x2009;&#x2009;kDa (TDP-43) regulates RNA processing and forms neuropathological aggregates in patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Investigating TDP-43 post-translational modifications, we discovered that K84 acetylation reduced nuclear import whereas K136 acetylation impaired RNA binding and splicing capabilities of TDP-43. Such failure of RNA interaction triggered TDP-43 phase separation mediated by the C-terminal low complexity domain, leading to the formation of insoluble aggregates with pathologically phosphorylated and ubiquitinated TDP-43. Introduction of acetyl-lysine at the identified sites via amber suppression confirmed the results from site-directed mutagenesis. K84-acetylated TDP-43 showed cytoplasmic mislocalization, and the aggregation propensity of K136-acetylated TDP-43 was confirmed. We generated antibodies selective for TDP-43 acetylated at these lysines, and found that sirtuin-1 can potently deacetylate K136-acetylated TDP-43 and reduce its aggregation propensity. Thus, distinct lysine acetylations modulate nuclear import, RNA binding and phase separation of TDP-43, suggesting regulatory mechanisms for TDP-43 pathogenesis.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garcia Morato</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8061-7841</Identifier><AffiliationInfo><Affiliation>Laboratory of Functional Neurogenetics, Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hans</LastName><ForeName>Friederike</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Laboratory of Functional Neurogenetics, Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Zweydorf</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feederle</LastName><ForeName>Regina</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3981-367X</Identifier><AffiliationInfo><Affiliation>Institute for Diabetes and Obesity, Monoclonal Antibody Core Facility, Helmholtz Munich, 85764, Neuherberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 81377, M&#xfc;nchen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Els&#xe4;sser</LastName><ForeName>Simon J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0001-8724-4849</Identifier><AffiliationInfo><Affiliation>Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 17165, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skodras</LastName><ForeName>Angelos A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Molecular Imaging Unit, Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gloeckner</LastName><ForeName>Christian Johannes</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0001-6494-6944</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Core Facility for Medical Bioanalytics (CFMB), Institute for Ophthalmic Research, Center for Ophthalmology, University of T&#xfc;bingen, 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buratti</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Molecular Pathology Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), 34149, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuropathology, University Hospital T&#xfc;bingen, 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahle</LastName><ForeName>Philipp J</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0002-8587-1731</Identifier><AffiliationInfo><Affiliation>Laboratory of Functional Neurogenetics, Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, 72076, T&#xfc;bingen, Germany. philipp.kahle@uni-tuebingen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 72076, T&#xfc;bingen, Germany. philipp.kahle@uni-tuebingen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, University of T&#xfc;bingen, 72076, T&#xfc;bingen, Germany. philipp.kahle@uni-tuebingen.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="C447939">SIRT1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="D056564">Sirtuin 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>K3Z4F929H6</RegistryNumber><NameOfSubstance UI="D008239">Lysine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000107" MajorTopicYN="N">Acetylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="Y">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008239" MajorTopicYN="Y">Lysine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056564" MajorTopicYN="Y">Sirtuin 1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>10</Day><Hour>5</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35264561</ArticleId><ArticleId IdType="pmc">PMC8907366</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-28822-7</ArticleId><ArticleId IdType="pii">10.1038/s41467-022-28822-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Buratti E, Baralle FE. The multiple roles of TDP-43 in pre-mRNA processing and gene expression regulation. RNA Biol. 2010;7:420&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">20639693</ArticleId></ArticleIdList></Reference><Reference><Citation>Sephton CF, Cenik B, Kutluk Cenik B, Herz J, Yu G. TDP-43 in central nervous system development and function: clues to TDP-43-associated neurodegeneration. Biol. Chem. 2012;393:589&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3537500</ArticleId><ArticleId IdType="pubmed">22944662</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratti A, Buratti E. Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins. J. Neurochem. 2016;138:95&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">27015757</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006;351:602&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton MJ, et al. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J. Biol. Chem. 2008;283:13302&#x2013;13309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442318</ArticleId><ArticleId IdType="pubmed">18305110</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, et al. Structural determinants of the cellular localization and shuttling of TDP-43. J. Cell Sci. 2008;121:3778&#x2013;3785.</Citation><ArticleIdList><ArticleId IdType="pubmed">18957508</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinarbasi ES, et al. Active nuclear import and passive nuclear export are the primary determinants of TDP-43 localization. Sci. Rep. 2018;8:7083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935693</ArticleId><ArticleId IdType="pubmed">29728608</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Baralle FE. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J. Biol. Chem. 2001;276:36337&#x2013;36343.</Citation><ArticleIdList><ArticleId IdType="pubmed">11470789</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey JR, et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat. Neurosci. 2011;14:452&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108889</ArticleId><ArticleId IdType="pubmed">21358640</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, et al. Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J. 2001;20:1774&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC145463</ArticleId><ArticleId IdType="pubmed">11285240</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A, Bharathi V, Sivalingam V, Girdhar A, Patel BK. Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis. Front. Mol. Neurosci. 2019;12:25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, Wang L, Huntley ML, Perry G, Wang X. Pathomechanisms of TDP-43 in neurodegeneration. J. Neurochem. 2018;146:7&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6110993</ArticleId><ArticleId IdType="pubmed">29486049</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann. Neurol. 2008;64:60&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009;117:137&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Hans F, Eckert M, von Zweydorf F, Gloeckner CJ, Kahle PJ. Identification and characterization of ubiquitinylation sites in TAR DNA-binding protein of 43 kDa (TDP-43) J. Biol. Chem. 2018;293:16083&#x2013;16099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6187624</ArticleId><ArticleId IdType="pubmed">30120199</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen TJ, et al. An acetylation switch controls TDP-43 function and aggregation propensity. Nat. Commun. 2015;6:5845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4407365</ArticleId><ArticleId IdType="pubmed">25556531</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurel C, et al. A role for SUMOylation in the formation and cellular localization of TDP-43 aggregates in amyotrophic lateral sclerosis. Mol. Neurobiol. 2020;57:1361&#x2013;1373.</Citation><ArticleIdList><ArticleId IdType="pubmed">31728929</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Wander CM, Yuan C-X, Bereman MS, Cohen TJ. Acetylation-induced TDP-43 pathology is suppressed by an HSF1-dependent chaperone program. Nat. Commun. 2017;8:82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5517419</ArticleId><ArticleId IdType="pubmed">28724966</ArticleId></ArticleIdList></Reference><Reference><Citation>Maharana S, et al. RNA buffers the phase separation behavior of prion-like RNA binding proteins. Science. 2018;360:918&#x2013;921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6091854</ArticleId><ArticleId IdType="pubmed">29650702</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JR, et al. RNA binding antagonizes neurotoxic phase transitions of TDP-43. Neuron. 2019;102:321&#x2013;338 e328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472983</ArticleId><ArticleId IdType="pubmed">30826182</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentmann E, et al. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43) J. Biol. Chem. 2012;287:23079&#x2013;23094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3391091</ArticleId><ArticleId IdType="pubmed">22563080</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y-J, et al. The dual functions of the extreme N-terminus of TDP-43 in regulating its biological activity and inclusion formation. Hum. Mol. Genet. 2013;22:3112&#x2013;3122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3699067</ArticleId><ArticleId IdType="pubmed">23575225</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, et al. A molecular grammar governing the driving forces for phase separation of prion-like RNA binding proteins. Cell. 2018;174:688&#x2013;699 e616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6063760</ArticleId><ArticleId IdType="pubmed">29961577</ArticleId></ArticleIdList></Reference><Reference><Citation>Voigt A, et al. TDP-43-mediated neuron loss in vivo requires RNA-binding activity. PLoS ONE. 2010;5:e12247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2923622</ArticleId><ArticleId IdType="pubmed">20806063</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukavsky PJ, et al. Molecular basis of UG-rich RNA recognition by the human splicing factor TDP-43. Nat. Struct. Mol. Biol. 2013;20:1443&#x2013;1449.</Citation><ArticleIdList><ArticleId IdType="pubmed">24240615</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang C-H, et al. Structural analysis of disease-related TDP-43 D169G mutation: linking enhanced stability and caspase cleavage efficiency to protein accumulation. Sci. Rep. 2016;6:21581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4756693</ArticleId><ArticleId IdType="pubmed">26883171</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M. Molecular neuropathology of TDP-43 proteinopathies. Int. J. Mol. Sci. 2009;10:232&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2662455</ArticleId><ArticleId IdType="pubmed">19333444</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiesel FC, et al. Knockdown of transactive response DNA-binding protein (TDP-43) downregulates histone deacetylase 6. EMBO J. 2010;29:209&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2808372</ArticleId><ArticleId IdType="pubmed">19910924</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryson DI, et al. Continuous directed evolution of aminoacyl-tRNA synthetases. Nat. Chem. Biol. 2017;13:1253&#x2013;1260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5724969</ArticleId><ArticleId IdType="pubmed">29035361</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawakami I, Arai T, Hasegawa M. The basis of clinicopathological heterogeneity in TDP-43 proteinopathy. Acta Neuropathol. 2019;138:751&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6800885</ArticleId><ArticleId IdType="pubmed">31555895</ArticleId></ArticleIdList></Reference><Reference><Citation>Conicella AE, Zerze GH, Mittal J, Fawzi NL. ALS mutations disrupt phase separation mediated by alpha-helical structure in the TDP-43 low-complexity C-terminal domain. Structure. 2016;24:1537&#x2013;1549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5014597</ArticleId><ArticleId IdType="pubmed">27545621</ArticleId></ArticleIdList></Reference><Reference><Citation>Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb. Perspect. Biol. 2014;6:a018713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3970420</ArticleId><ArticleId IdType="pubmed">24691964</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang BL. Could sirtuin activities modify ALS onset and progression? Cell. Mol. Neurobiol. 2017;37:1147&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pubmed">27942908</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z, et al. Neurodegeneration-associated TDP-43 interacts with fragile X mental retardation protein (FMRP)/Staufen (STAU1) and regulates SIRT1 expression in neuronal cells. J. Biol. Chem. 2012;287:22560&#x2013;22572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3391095</ArticleId><ArticleId IdType="pubmed">22584570</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chi&#xf2; A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 2014;17:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Baizabal-Carvallo JF, Jankovic J. Parkinsonism, movement disorders and genetics in frontotemporal dementia. Nat. Rev. Neurol. 2016;12:175&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">26891767</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal J, et al. The acetylation of lysine-376 of G3BP1 regulates RNA binding and stress granule dynamics. Mol. Cell. Biol. 2019;39:e00052-19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6817755</ArticleId><ArticleId IdType="pubmed">31481451</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Sun Y, Liu W, Dong J, Chen J. SIRT1 mediates the role of RNA-binding protein QKI 5 in the synthesis of triglycerides in non-alcoholic fatty liver disease mice via the PPARalpha/FoxO1 signaling pathway. Int. J. Mol. Med. 2019;43:1271&#x2013;1280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6365049</ArticleId><ArticleId IdType="pubmed">30664220</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, et al. HSP70 chaperones RNA-free TDP-43 into anisotropic intranuclear liquid spherical shells. Science. 2021;371:6529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8286096</ArticleId><ArticleId IdType="pubmed">33335017</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Lee VM-Y, Trojanowski JQ. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies. Neuropathology. 2010;30:103&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3131978</ArticleId><ArticleId IdType="pubmed">20102519</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhary C, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009;325:834&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">19608861</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes E, Shorter J. The molecular language of membraneless organelles. J. Biol. Chem. 2019;294:7115&#x2013;7127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6509512</ArticleId><ArticleId IdType="pubmed">30045872</ArticleId></ArticleIdList></Reference><Reference><Citation>Els&#xe4;sser SJ, Ernst RJ, Walker OS, Chin JW. Genetic code expansion in stable cell lines enables encoded chromatin modification. Nat. Methods. 2016;13:158&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888942</ArticleId><ArticleId IdType="pubmed">26727110</ArticleId></ArticleIdList></Reference><Reference><Citation>Kametani F, et al. Mass spectrometric analysis of accumulated TDP-43 in amyotrophic lateral sclerosis brains. Sci. Rep. 2016;6:23281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793195</ArticleId><ArticleId IdType="pubmed">26980269</ArticleId></ArticleIdList></Reference><Reference><Citation>Hans F, et al. UBE2E ubiquitin-conjugating enzymes and ubiquitin isopeptidase Y regulate TDP-43 protein ubiquitination. J. Biol. Chem. 2014;289:19164&#x2013;19179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4081952</ArticleId><ArticleId IdType="pubmed">24825905</ArticleId></ArticleIdList></Reference><Reference><Citation>North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol. Cell. 2003;11:437&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">12620231</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyon D, et al. FLASH assembly of TALENs for high-throughput genome editing. Nat. Biotechnol. 2012;30:460&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3558947</ArticleId><ArticleId IdType="pubmed">22484455</ArticleId></ArticleIdList></Reference><Reference><Citation>Emiliani S, Fischle W, Van Lint C, Al-Abed Y, Verdin E. Characterization of a human RPD3 ortholog, HDAC3. Proc. Natl Acad. Sci. USA. 1998;95:2795&#x2013;2800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19648</ArticleId><ArticleId IdType="pubmed">9501169</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischle W, et al. A new family of human histone deacetylases related to Saccharomyces cerevisiae HDA1p. J. Biol. Chem. 1999;274:11713&#x2013;11720.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206986</ArticleId></ArticleIdList></Reference><Reference><Citation>Warnecke A, Sandalova T, Achour A, Harris RA. PyTMs: a useful PyMOL plugin for modeling common post-translational modifications. BMC Bioinform. 2014;15:370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4256751</ArticleId><ArticleId IdType="pubmed">25431162</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Riverol Y, et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res. 2019;47:D442&#x2013;D450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323896</ArticleId><ArticleId IdType="pubmed">30395289</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>